1 |
Qin H, You C, Yan F, Tan K, Xu C, Zhao R, Ekpo MD, Tan S. Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1062765] [Reference Citation Analysis]
|
2 |
Liang T, Li D, Zunong J, Li M, Amaerjiang N, Xiao H, Khattab NM, Vermund SH, Hu Y. Interplay of Lymphocytes with the Intestinal Microbiota in Children with Nonalcoholic Fatty Liver Disease. Nutrients 2022;14:4641. [DOI: 10.3390/nu14214641] [Reference Citation Analysis]
|
3 |
Ortiz-lópez N, Fuenzalida C, Dufeu MS, Pinto-león A, Escobar A, Poniachik J, Roblero JP, Valenzuela-pérez L, Beltrán CJ. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 2022;13:954869. [DOI: 10.3389/fimmu.2022.954869] [Reference Citation Analysis]
|
4 |
Li B, Su R, Yan H, Liu J, Gao C, Li X, Wang C. Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells. Front Immunol 2022;13:907729. [DOI: 10.3389/fimmu.2022.907729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Zhang M, Zhang Y, Jiao X, Lai L, Qian Y, Sun B, Yang W. Identification and validation of immune related core transcription factors GTF2I in NAFLD. PeerJ 2022;10:e13735. [PMID: 35891648 DOI: 10.7717/peerj.13735] [Reference Citation Analysis]
|